BERLIN -- Adding durvalumab (Imfinzi) to bacillus Calmette-Guérin (BCG) induction and maintenance therapy significantly ...
To kick things off, we'll set the stage on what defines non-muscle invasive bladder cancer and how we triage patient ...
This is the first meta-analysis comparing the overall survival of patients with limited-stage small cell bladder cancer who underwent radical surgery with platinum-based perioperative chemotherapy vs ...
AstraZeneca's Imfinzi with BCG delivers 32% lower recurrence risk in high-risk bladder cancer. Read more here.
Results presented by AstraZeneca from its phase 3 trial of Imfinzi in patients with high-risk, non-muscle invasive bladder ...
A novel drug-delivery system has demonstrated effectiveness in treating specific bladder cancer patients whose tumors ...
Discover a study exploring how bladder cancer organoids advance personalised drug testing, reveal tumour heterogeneity, and ...
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously ...
The 2025 ESMO annual meeting featured a urothelial carcinoma proffered paper session and a presentation by Dr. Maria De Santis discussing POTOMAC, a phase 3, randomized, open-label, trial of ...
The BladderPath trial indicates that mpMRI can expedite MIBC treatment and improve bladder cancer-specific survival compared to traditional TURBT. The study showed a significant improvement in BCSS ...
What Is Zusduri Used For? Zusduri is used to treat a certain type of recurrent, persistent bladder cancer known as LG-IR-NMIBC. About 75% of people with bladder cancer present with non-muscle invasive ...
A HALF-HOUR scan could nearly halve bladder cancer deaths, a study suggests. Giving patients an MRI scan before the usual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback